Mankind Pharma completes Rs 13,768 crore BSV acquisition
BSV, has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and boasts of a robust branded product portfolio across women's health, fertility, critical care and immunoglobulins.
Mankind Pharma on Wednesday said it has completed the transaction to acquire Bharat Serums and Vaccines Ltd (BSV), for a consideration of Rs 13,768 crore.
This strategic move marks a significant leap for the company, positioning it as a market leader in the Indian women's health and fertility drug market alongside access to other high entry barrier products in critical care segment with established complex R&D tech platforms, the drug maker said in a statement.
BSV, has developed recombinant and niche biologic products in-house, demonstrating its strong R&D capabilities and boasts of a robust branded product portfolio across women's health, fertility, critical care and immunoglobulins.
"Today, we warmly welcome BSV's 2,500 plus members to Mankind family adding a new chapter to our exciting journey and setting the stage for accelerated growth," Mankind Pharma Vice-chairman and Managing Director Rajeev Juneja stated.
Sanjiv Navangul, MD & CEO, BSV, said that being a part of the Mankind Pharma family makes BSV bigger, stronger and better.
"Together, we will now be able to ensure wider access of our specialised and indigenously developed complex treatments to millions of patients in India and across the globe. We will together unlock new possibilities, explore opportunities and maximize potential that will help achieve our priorities and business goals," he added.
In July this year, Mankind had announced that it will acquire 100 per cent stake in BSV.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Power of Compounding: Monthly savings Rs 3,000; here's how you can generate Rs 1.58 crore fund through step up SIP
NTPC Q2 FY25 Results Preview: Maharatna PSU's profit likely to grow by one-fifth, margin may improve by 190 bps
What senior citizens can get on Rs 6 lakh, Rs 12 lakh and Rs 18 lakh investment in Amrit Vrishti FDs
SBI 444-day FD vs ICICI Bank 15-month FD vs Central Bank of India 444-day FD: What will be maturity amounts on Rs 10 lakh investment for general and senior citizens? Know here
SBI Senior Citizen 5-year FD vs SBI General Citizen 5-year FD: Here's what general and senior citizens will get on Rs 3 lakh, Rs 6 lakh, and Rs 9 lakh investments
Top 7 Mutual Funds With up to 74% Return in 1 Year: No. 1 fund has converted Rs 5 lakh investment into Rs 8.69 lakh; know about others
Stocks to BUY for Long Term: Get up to 74% return in these 2 largecap, 1 midcap, 2 smallcap scrips | Check targets by brokerage
Shares to buy for long term | Analysts suggest buying 5 largecap, 4 midcap, 1 smallcap stocks; check out targets
PNB Palaash Green Deposit 1204 Days FD vs SBI Green Deposit 1111 Days FD: What will be maturity amounts for general and senior citizens on Rs 5 lakh and Rs 9 lakh investments
10:01 AM IST